This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Alport Syndrome

Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants

Sponsored by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

About this trial

Last updated 4 years ago

Study ID

XHEC-C-2021-070-2

Status

Not yet recruiting

Type

Interventional

Phase

N/A

Placebo

No

Accepting

18-75 Years
30 to 50 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Started 4 years ago

What is this trial about?

Alport syndrome (AS) is the second most common monogenic cause of end-stage renal failure (ESRF). AS is caused by variants in the COL4A3, COL4A4, and COL4A5 genes, which encode for the a3, a4, and a5 chains of type IV collagen. This trial is a prospective, randomized, controlled and multicenter trial. Mainly to assess the safety and efficacy of ramipril in Alport syndrome patients with variants of COL4A3/COL4A4/COL4A5.

What are the participation requirements?

Yes

Inclusion Criteria

1. Age: 30-50 Years;

2. Sex: All;

3. Alport syndrome patients with variants of COL4A3/COL4A4/COL4A5; hematuria or microalbuminuria; eGFR>90 mL/min/1.73m2;

4. Patients with microscopic hematuria only;

5. Patients with microscopic hematuria and microalbuminuria: 30-300mg/24h or urine albumin/creatinine: 30-300mg/g;

6. No angiotensin converting enzyme inhibitor (ACEI) and other renin-angiotensin system inhibitors (including angiotensin II receptor antagonists, etc.) treatment.

No

Exclusion Criteria

1. With primary or secondary kidney disease, including IgA nephropathy, membranous nephropathy, lupus nephropathy, benign renal arterioles, etc.;

2. Patients with a history of angioedema;

3. Hypovolemia or hypotension (systolic blood pressure less than 90mmHg and/or diastolic blood pressure less than 60mmHg);

4. Pregnant and lactating women;

5. Patients with bilateral renal artery stenosis or unilateral renal artery stenosis with solitary kidney;

6. Hyperkalemia, blood potassium>5.5mmol/L;

7. Severe aortic stenosis, severe mitral stenosis;

8. Treatment of drug allergy;

9. Hypertension or other diseases that may require treatment with angiotensin-converting enzyme inhibitors;

10. Disagree to participate in this research.

Locations

Location

Status